Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: Two clinical trials

Clinical Breast Cancer

Volumn 10, Issue 5, 2010, Pages 352-358

  Fornier, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epothilone; Phase III trials; Resistant breast cancer

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CISPLATIN; IXABEPILONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ANEMIA; ARTHRALGIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MONOTHERAPY; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77957782504     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.046     Document Type: Review

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2010. CA Cancer J Clin 2010; [e-pub ahead of print].
2. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treat-ment of metastatic breast cancer. Oncologist 2004; 9:617-32.
3. Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 2008; 8:224-33.
4. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10(suppl 3):20-9.
5. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005; 89(suppl 1):S9-15.
6. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210-7.
7. Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III tri-als. Presented at: 2008 ASCO Breast Cancer Symposium; September 5-7, 2008; Washington, DC Abstract 186.
8. Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008; 63:157-66.
9. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmaco-kinetics of ixabepilone. Cancer Chemother Pharmacol 2009; 63:201-12.
10. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothi-lones in patients with advanced solid tumors. Oncologist 2008; 13:1207-23.
11. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 2008; 35(suppl 2):S1-14.
12. Atzori F, Fornier M. Epothilones in breast cancer: current status and future direc-tions. Expert Rev Anticancer Ther 2008; 8:1299-311.
13. Bunnell C, Vahdat L, Schwartzberg L, et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008; 8:234-41.
14. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407-14.
15. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-34.
16. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant meta-static breast cancer. J Clin Oncol 2007; 25:3399-406.
17. Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepi-lone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27:526-34.
18. Vahdat L, Fein LE, Karwal MW, et al. Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies. Presented at: 31st San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2008; San Antonio, TX. Poster 6117.
19. Rugo HS, Roche H, Thomas E, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. Presented at: 31st San Antonio Breast Cancer Sympo-sium (SABCS); December 10-14, 2008; San Antonio, TX. Poster 3057.
20. Roche H, Li R, Ro J, et al. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. Presented at: 31st San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2008; San Antonio, TX. Poster 2015.
21. Conte P, Roche H, Perez E, et al. Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthra-cycline and taxane in 2 large phase III studies. Presented at: 31st San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2008; San Antonio, TX. Poster 61 14.
22. Pivot X, Lee RK, Thomas ES, et al. Phase III study of ixabepilone plus capecitabi-ne in patients with metastatic breast cancer (MBC) resistant to anthracyclines/taxanes: subgroup analysis by estrogen receptor (ER) status. Presented at: 2007 ASCO Breast Cancer Symposium; September 7-8, 2007; San Francisco, CA. Abstract 221.
23. IXEMPRA® (Ixabepilone) Kit for Injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2009.
24. Perez E, Pivot X, Vrdoljak E, et al. A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Presented at: 31st San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2008; San Antonio, TX. Poster 6140.
25. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthra-cycline treatment. J Clin Oncol 2008; 26:3950-7.
26. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-23.
27. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
28. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 2007; 25:3415-20.
29. Tolaney SM, Najita J, Chen W, et al. A phase II study of ixabepilone plus trastu-zumab for metastatic HER2-positive breast cancer. Presented at: 31st San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2008; San Antonio, TX. Poster 3137.
30. Moulder SL, Wang M, Gradishar W, et al. A phase II trial of trastuzumab, weekly ixabepilone and carboplatin (TIC) in patients with HER2/neupositive (HER2+) metastatic breast cancer (MBC): a trial coordinated by the Eastern Cooperative Oncology Group. Presented at: 2007 ASCO Breast Cancer Symposium; September 7-8; San Francisco, CA. Abstract 152.